Stellar Biotechnologies president and CEO Frank Oakes today presented at the Rodman & Renshaw 2014 Global Investment Conference, where more than 200 biotech, healthcare, technology, natural resources and growth companies are presenting to an audience of more than 1,500 attendees. The conference will be held at the New York Palace Hotel in New York City, September 8-11, 2014.

Oakes took the stage to highlight the Stellar’s position and operations a sustainable manufacturer of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets.

This versatile molecule can be combined with a disease-targeting agent to create a novel immunotherapy, or used alone to assess the body’s immune response.  KLH can only be obtained from a scarce marine source, the Giant Keyhole Limpet, a shelled species native to Southern California and Mexico.

Stellar has developed a patented method for harvesting KLH without harming the Giant Keyhole Limpet.  The company’s production facilities represent breakthrough achievements such as the first-ever ability to sustain generations of the source in controlled, land-based facilities.

Stellar aims to utilize this method to meet the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production and developing KLH-based active immunotherapies.

The webcast of Oakes presentation is archived on Stellar’s website at: http://ir.stellarbiotechnologies.com/events-calendar

Visit www.stellarbiotech.com and the KLH knowledge base www.klhsite.org.